GlassScriptPhysician profile
Joel W Phillips
NPI 1083724207
$5,430.09
in general payments reported to CMS, 2019-2025
27 companies · $23.06 in 2025
The $23.06 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $797 · 2020: $625 · 2021: $855 · 2022: $959 · 2023: $1,317 · 2024: $853 · 2025: $23.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,173 · Consulting Fee: $19.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,173.30 |
| Consulting Fee | $19.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,225.05 | 2019-2024 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $867.41 | 2019-2024 | Fasenra, Tezspire, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $579.97 | 2020-2024 | Glassia, Hyqvia, Cuvitru |
| Genzyme Corporation | $564.41 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $325.09 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $269.56 | 2019-2024 | Dupixent |
| Csl Behring | $249.93 | 2019-2024 | Hizentra, Haegarda |
| Teva Pharmaceuticals USA, INC. | $244.63 | 2019-2022 | |
| Midsouth Orthopedics INC. | $217.61 | 2023 | |
| Amgen INC. | $179.90 | 2021-2024 | Tezspire |
| Novo Nordisk INC | $144.61 | 2022-2024 | Rybelsus, Ozempic |
| Genentech USA, INC. | $90.56 | 2019-2021 | |
| Grifols USA, LLC | $88.46 | 2019-2023 | Prolastin-C Liquid |
| Pfizer INC. | $59.80 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.55 | 2020-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $40.28 | 2022 | |
| Shire North American Group INC | $38.14 | 2019 | |
| Optinose US, INC. | $35.70 | 2019-2024 | |
| Lucid Diagnostics INC. | $22.38 | 2024 | |
| Adma Biomanufacturing LLC | $19.54 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.89 | 2019 | |
| Incyte Corporation | $18.06 | 2022 | |
| Horizon Therapeutics Plc | $17.38 | 2020 | |
| Kaleo, INC. | $15.52 | 2022 | |
| Abbvie INC. | $14.13 | 2021 | |
| Alk-Abello, INC | $13.62 | 2022 | |
| Currax Pharmaceuticals LLC | $12.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.